for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syndax Pharmaceuticals Inc

SNDX.OQ

Latest Trade

8.70USD

Change

-0.01(-0.11%)

Volume

156,595

Today's Range

8.44

 - 

8.79

52 Week Range

3.39

 - 

11.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.71
Open
8.71
Volume
156,595
3M AVG Volume
3.12
Today's High
8.79
Today's Low
8.44
52 Week High
11.04
52 Week Low
3.39
Shares Out (MIL)
27.14
Market Cap (MIL)
240.43
Forward P/E
-4.72
Dividend (Yield %)
--

Next Event

Q3 2019 Syndax Pharmaceuticals Inc Earnings Release

Latest Developments

More

Syndax Pharmaceuticals Files For Mixed Shelf Of Up To $300 Mln

Syndax Pharmaceuticals Q2 Loss Per Share $0.47

Syndax Pharmaceuticals Announces FDA Clearance Of Ind Application For Targeted Menin Inhibitor Sndx-5613 For Relapsed/Refractory Acute Leukemias

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Industry

Biotechnology & Drugs

Contact Info

Building D, 35 Gatehouse Dr Fl 3

+1.781.4191400

http://www.syndax.com/

Executive Leadership

Dennis G. Podlesak

Independent Chairman of the Board

Michael A. Metzger

President, Chief Operating Officer, Director

Briggs W. Morrison

Chief Executive Officer, Director

Richard P. Shea

Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer

Michael L. Meyers

Senior Vice President, Chief Development Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.220

2017

-2.900

2018

-2.920

2019(E)

-1.877
Price To Earnings (TTM)
--
Price To Sales (TTM)
158.60
Price To Book (MRQ)
4.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-83.85
Return on Equity (TTM)
-67.85

Latest News

BRIEF-Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79

* SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

BRIEF-Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS - PHASE 2 ENCORE 601 PD-(L)1 REFRACTORY MELANOMA COHORT DATA AND MELANOMA REGISTRATION STRATEGY DISCLOSURE FORTHCOMING IN 2Q18

BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca

* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update

BRIEF-Syndax announces $25 million registered direct offering of common stock

* Syndax announces $25 million registered direct offering of common stock

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc - SEC filing

BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer

* Syndax announces dosing of first patient in pivotal trial of entinostat for treatment of advanced or recurrent breast cancer in Japan by partner kyowa hakko kirin

BRIEF-Syndax Pharmaceuticals Q2 loss per share $0.70

* Syndax Pharmaceuticals reports second quarter 2017 financial results and provides clinical and business update

BRIEF-Syndax prices public offering of common stock

* Pricing of an underwritten public offering of 3.7 million shares of its common stock at a price to public of $13.25 per share Source text for Eikon: Further company coverage:

BRIEF-Syndax Pharma to offer common stock in public offering

* Syndax pharmaceuticals inc- it plans to offer and sell $50 million of its common stock in an underwritten public offering Source text for Eikon: Further company coverage:

BRIEF-Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda

* Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda (pembrolizumab) for the treatment of advanced melanoma

BRIEF-Syndax Pharmaceuticals announces advancement of encore 601

* Syndax Pharmaceuticals announces advancement of encore 601 in non-small cell lung cancer patients with disease progression on or after PD-1 therapies

BRIEF-Syndax Pharmaceuticals Q1 loss per share $0.71

* Syndax Pharmaceuticals reports first quarter 2017 financial results and provides clinical and business update

BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit

* Syndax Pharmaceuticals announces expansion of encore 601/keynote 142, ongoing phase 2 clinical collaboration with a subsidiary of Merck

BRIEF-Syndax pharmaceuticals reports Q4 loss per share $0.59

* Syndax Pharmaceuticals reports fourth quarter and year-end 2016 financial results and provides clinical and business update

BRIEF-Syndax appoints Richard Shea chief financial officer

* Richard P. Shea is stepping down from position on Syndax board of directors and is joining CFO effective February 13, 2017 Source text for Eikon: Further company coverage:

BRIEF-Syndax appoints Lisa Coussens to scientific advisory board

* Syndax appoints Lisa Coussens, ph.d., to scientific advisory board Source text for Eikon: Further company coverage:

BRIEF-Domain Partners VI L.P reports 9.6 pct passive stake in Syndax Pharmaceuticals as of Dec 31, 2016

* Domain Partners VI L.P reports 9.6 percent passive stake in Syndax Pharmaceuticals Inc as of December 31, 2016 - Sec filing Source text (http://bit.ly/2i6xxuh) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up